Eyal Flom
Director/Board Member at INNOCAN PHARMA CORPORATION
Net worth: 501 183 $ as of 30/05/2024
Eyal Flom active positions
Companies | Position | Start | End |
---|---|---|---|
INNOCAN PHARMA CORPORATION | Director/Board Member | 24/09/2019 | - |
Corporate Secretary | 21/01/2020 | - | |
REVIUM RECOVERY INC. | Director/Board Member | - | - |
Israeli Pharmaceutical Association | General Counsel | 31/03/1995 | - |
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Director/Board Member | - | - |
Career history of Eyal Flom
Former positions of Eyal Flom
Companies | Position | Start | End |
---|---|---|---|
NUREXONE BIOLOGIC INC. | Director/Board Member | 14/06/2022 | 07/05/2023 |
Training of Eyal Flom
University of Derby | Masters Business Admin |
Tel-Aviv University | Graduate Degree |
Statistics
International
Israel | 6 |
Canada | 2 |
United Kingdom | 2 |
Operational
Director/Board Member | 4 |
Corporate Secretary | 1 |
Masters Business Admin | 1 |
Sectoral
Health Technology | 4 |
Consumer Services | 3 |
Distribution Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
INNOCAN PHARMA CORPORATION | Health Technology |
NUREXONE BIOLOGIC INC. | Health Technology |
REVIUM RECOVERY INC. | Distribution Services |
Private companies | 2 |
---|---|
Israeli Pharmaceutical Association | |
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Part of NurExone Biologic, Inc., NurExone Biologic Ltd. is an Israeli company that offers a new approach to Spinal Cord Injury treatment. The company is based in Bnei-Brak, Israel. The company believes that intranasal exosome administration offers an alternative to cell transplantation. The company was founded in 2020 by Yoram Nathan Drucker. Lior Shaltiel has been the CEO of the company since 2021. NurExone Biologic was acquired by EnerSpar Corp. on June 15, 2022. | Health Technology |
- Stock Market
- Insiders
- Eyal Flom
- Experience